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List of Abbreviations 
TLS – tertiary lymphoid structure 
E-TLS – early TLS  
PFL-TLS – primary follicle-like TLS  
SFL-TLS – secondary follicle-like TLS 
GC – germinal center 
LSCC – lung squamous cell carcinoma 
NSCLC – non-small cell lung cancer 
HEV – high endothelial venule 
DC – dendritic cell 
FDC – follicular dendritic cell 
LT – lymphotoxin 
TFH – T follicular helper cell 
Treg –  T regulatory cell 
TIL – tumor infiltrating lymphocyte 
SLO – secondary lymphoid organ 
iBALT – inducible bronchus associated lymphoid tissue 
COPD – chronic obstructive pulmonary disease  
FFPE – formalin-fixed paraffin-embedded 
HPF – high-power field  
H&E – hematoxylin and eosin 
IHC – immunohistochemistry 
IF – immunofluorescence 
ROC – Receiver Operating Characteristics 
PFS – progression-free survival 
DFS – disease-free survival  
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ABSTRACT 
 
In solid tumors, the presence of lymph node-like structures called tertiary lymphoid structures 
(TLS) is associated with improved patient survival. However, little is known about how TLS 
form in cancer, how their function affects survival, and whether they are affected by cancer 
therapy. In this study, we used multi-spectral microscopy, quantitative pathology and gene 
expression profiling to analyze TLS formation in human lung squamous cell carcinoma 
(LSCC) and in an experimental model of lung TLS induction. We identified a niche of 
CXCL13+ perivascular and CXCL12+LTB+ and PD-L1+ epithelial cells supporting TLS 
formation. We also characterized sequential stages of TLS maturation in LSCC culminating in 
the formation of germinal centers (GC). In untreated patients, TLS density was the strongest 
independent prognostic marker. Further, TLS density correlated with GC formation and 
expression of adaptive immune response-related genes. In patients treated with neoadjuvant 
chemotherapy, TLS density was similar but GC formation was impaired and the prognostic 
value of TLS density was lost. Corticosteroids are co-administered with chemotherapy to 
manage side effects in LSCC patients, so we evaluated whether they impaired TLS 
development independently of chemotherapy. TLS density and GC formation were each 
reduced in chemotherapy-naive LSCC patients treated with corticosteroids before surgery, 
compared to untreated patients, a finding that we confirmed in the experimental model of lung 
TLS induction. Overall, our results highlight the importance of GC formation in TLS during 
tumor development and treatment. 
 
PRECIS 
 
Corticosteroid treatment during chemotherapy negatively affects the development of tertiary 
lymphoid structures and abrogates their prognostic value in lung cancer patients. 
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INTRODUCTION 
 
Tertiary lymphoid structures (TLS) resemble follicles of secondary lymphoid organs (SLO) 
both by structure and function and develop in response to chronic inflammation (1) and 
cancer (2,3). The presence of germinal centers (GC) within TLS correlates with exacerbated 
autoimmunity and transplant rejection due to the generation of auto-reactive B cells and high 
endothelial venules (HEVs) (1). In models for infection TLS serve as priming sites for T cells 
and contribute to pathogen clearance (4,5). The first prognostic analysis of TLS in human 
cancer showed that TLS containing GC correlate with improved survival for patients with 
hepatocellular carcinoma (6). Further studies showed that either total TLS numbers or the 
numbers of TLS-associated immune cells including follicular helper T (TFH) cells, follicular B 
cells, mature dendritic cells (DCs) and HEVs are associated with prolonged survival in many 
different tumor types (3,7-10). Specifically in non-small cell lung cancer (NSCLC), the 
number of CD208+ (DC-LAMP+) antigen presenting mature DCs, which reside in T cell 
areas of TLS, significantly correlated with improved survival (11), especially in combination 
with the number of CD8+ T cells (12) or follicular B cells (13). Tumor-associated TLS 
provide the necessary specialized vasculature and chemo-attractants that allows T cell 
infiltration (14) and significantly correlate with tumor-infiltrating T cells and plasma cells 
(13,15,16). B cell and T cell receptor sequencing data show clonal expansion of lymphocytes 
in tumor-associated TLS suggesting a direct role for TLS in the priming of anti-tumor 
immunity (17-19). Moreover, the application of CXCL13 or lymphotoxin (LT) – two 
components of a positive feedback-loop orchestrating the organogenesis of SLO (20) and TLS 
development in adult mice (21) – resulted in tumor control in models of colorectal cancer 
(CRC) (22) or melanoma (23). In order to normalize tumor-associated blood vessels, 
Johansson-Percival et al. delivered LIGHT to such vessels resulting in susceptibility of RIP-
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TAg pancreatic tumors to treatment with anti-cancer vaccines and immune checkpoint 
inhibition. Interestingly, targeting LIGHT to tumor-associated blood vessels induced 
formation of TLS, which can be explained by the fact that LIGHT is an essential ligand for 
SLO and TLS development (24). In human pancreatic ductal adenocarcinoma, TLS developed 
in response to GVAX immunotherapy in around 85% of patients and their presence is 
associated with an increased ratio of intratumoral Teffector:Treg cells, improved post-
vaccination responses and prolonged survival (25). 
In light of these studies, deliberate induction of tumor-associated TLS has been proposed as a 
novel immunotherapeutic approach (2,3). However, the mechanisms underlying TLS 
development in different human tissues are poorly understood and may be affected by the 
nature of the inflammatory stimulus and the organ-specific environments (7). In lungs for 
example, viral or bacterial stimuli activate the LT/CXCL13 or IL-17/CXCL12 pathway, 
respectively, resulting in the formation of TLS, also known as inducible bronchus associated 
lymphoid tissue (iBALT) (26). The LT/CXCL13 pathway is crucial for differentiation of 
follicular dendritic cells (FDC) and functional GC (26,27). Both pathways participate in TLS 
development in response to cigarette smoke or LPS, which is a major component of cigarette 
smoke (28), in patients and animal models of chronic obstructive pulmonary disease (COPD) 
(29,30). Cigarette smoke and inhaled particulates such as alum drive the release of IL1α by 
alveolar macrophages and lead to iBALT formation (31-33). Additional factors like CCL19, 
CCL21 and IL-22 also contribute to iBALT development (34,35) but which stimuli are 
upstream of these pathways is not known. A crucial role for B cells, T cells and DC in the 
generation and maintenance of TLS has been demonstrated in various animal models (35). 
Finally, Krautler et al. showed that ubiquitous perivascular PDGFRβ+ mesenchymal cells are 
the precursors of FDCs, which orchestrate B cell accumulation and TLS development in a 
LTβ receptor (LTBR)-dependent manner explaining why TLS can arise in any vascularized 
organ (36). The abovementioned chemokines and immune cells are linked to the presence of 
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TLS in human cancers (3,37). However, there is little information about the sequence of 
events that drive the development of tumor-associated TLS or about which features of TLS 
are relevant for patients’ survival. To address these questions we characterized the TLS-
associated microenvironment and TLS composition in human LSCC tissues and an 
experimental model of lung TLS induction. We identified three distinct maturation stages of 
TLS culminating in GC formation with significant relevance for patient survival and 
expression of adaptive immunity-related genes. Corticosteroids are frequently used to manage 
side effects of chemo- or radiotherapy or to treat other co-morbidities of cancer patients. Our 
data suggest that corticosteroids have a negative impact on TLS development and specifically 
on GC formation in LSCC patients and lungs of mice. 
 
METHODS 
 
Patient material 
Patient analyses were conducted according to the Declaration of Helsinki. Ethical approval for 
performing research on anonymized, archival patient material was obtained from the cantonal 
ethics commission Zurich (KEK-ZH-2013-0584 amendment 26.11.2015, KEK-ZH-29-2009 
amendment 20.05.2016) and Ethics Committee of Biomedical Research of Riga East 
University Hospital with signed informed consents.  
Samples from patients who underwent resection of LSCC regardless of tumor stage in 
University Hospital Zurich (USZ) were collected between 2003 and 2010, and were analyzed 
for their baseline and outcome clinical information retrospectively from the in-house 
diagnostic and treatment databases (n=245) by a clinical pathologist (AS) and a medical 
oncologist (ACF). Following criteria were used to exclude patients: Mixed tumor histology, 
prior diagnosis of a squamous cell carcinoma of head and neck or incomplete diagnostic and 
clinical data. Patients who passed the exclusion criteria were sorted by tumor stage and 
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similar proportions of early and late stage patients were selected for analysis (Zurich cohort, 
n=138, Table 1). These patients were followed-up until December 2015 (median follow-up 
time from diagnosis 1429 days).  
Information on patients who underwent resection of lung cancer in Riga Eastern Clinical 
University Hospital (Riga cohort, n=78) is provided in Supplementary methods and 
Supplementary Table S1. 
 
Histological evaluation 
The number of dense lymphocytic aggregates was quantified per 10x high-power field (HPF) 
in all tumor-containing hematoxylin and eosin (H&E)-stained diagnostic sections of the 
Zurich cohort. TLS density was calculated as the number of TLS per mm
2
 in peritumoral and 
intratumoral regions. A patient was considered as GC-positive if at least one TLS showed the 
characteristic morphology of proliferating centroblasts. The sample analyst (KS) was blinded 
for the patients’ clinical data at the time of histological evaluation. Further details provided in 
Supplementary methods. 
 
Gene expression analysis 
A representative set of 27 chemotherapy-naïve patients was selected to match the whole 
cohort for the variability of TLS density, survival and stage and included 10 TLS-low and 17 
TLS-high tumors. Full details on tissue preparation and qPCR data analysis according to the 
MIQE guidelines (38) are provided in Supplementary methods and Supplementary Fig. S1A 
and B. Primer sequences are shown in Supplementary Table S2. 
 
Immunostaining and quantitative pathology 
Antibodies and detection reagents used for immunostaining are listed in Supplementary 
Table S3. Full details on immunohistochemical (IHC) and immunofluorescent (IF) staining 
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protocols are provided in Supplementary methods. To analyze TLS maturation in different 
TLS density groups a set of 61 chemotherapy-naïve patients was selected to match the whole 
cohort for the variability of TLS density, survival and stage and included 24 TLS-low and 37 
TLS-high tumors (Supplementary Fig. S1C). To analyze the effects of neoadjuvant 
treatments 28 TLS-high patients treated with neoadjuvant chemotherapy (Zurich cohort) and 
all TLS-high patients that received neoadjuvant radiotherapy (Riga cohort, n=4) were selected. 
To analyze the effects of corticosteroids, chemotherapy-naïve patients of the Zurich cohort 
that had received corticosteroids before surgery to treat other comorbidities (n=15, 
Supplementary Table S4) were compared to patients without any steroid or chemotherapy 
treatment (n=43).  
For TLS maturation analysis slides were co-stained for CD21, CD23, and CXCL13. All dense 
lymphocytic aggregates irrespective of CD21/CD23 signal were imaged as multispectral HPF 
(200x) by Vectra 3.0 imaging system (PerkinElmer). Spectral unmixing is described in 
Supplementary methods. Each HPF image was evaluated for the TLS maturation stage as 
follows: early TLS (E-TLS), dense lymphocytic aggregates lacking CD21 and CD23 signal; 
primary follicle-like TLS (PFL-TLS), dense lymphocytic aggregates with CD21 but no CD23 
signal; secondary follicle-like TLS (SFL-TLS), dense lymphocytic aggregates with CD21 and 
CD23 signal. The proportion of TLS in each maturation stage was determined for each patient. 
To determine the size of GC, tissue segmentation algorithm of Inform software (PerkinElmer) 
was trained to recognize areas that co-expressed CD21 and CD23. The GC size was 
calculated as the average pixel count per GC area for each patient. Segmentation quality was 
verified for all images by the sample analyst (KS) who was blinded for the patients’ clinical 
data at the time of image analysis. Inappropriately segmented images were excluded from 
calculations. For the analysis of DCs and HEVs in the context of TLS maturation slides were 
co-stained for CD20, CD21, CD23, PNAD and DC-LAMP. All dense lymphocytic aggregates 
and all areas with PNAD and DC-LAMP signal were imaged and analyzed as above. 
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In vivo experiments 
All animal experiments were approved by the cantonal veterinary office Zurich (license 
number 127/2015) and conducted in accordance to the Swiss federal and cantonal law on 
animal protection. Female C57BL/6NRj mice (8-12-weeks-old) were obtained from Janvier 
Labs (Saint Berthevin, France) and maintained in specific pathogen-free facilities at the 
University of Zurich. Mice received intranalsal (i.n.) administration of alum ovalbumin (Ova) 
as described before (33) and received daily p.o. dexamethasone (0.3 mg/kg) or PBS. Full 
details on treatment protocols and analysis are provided in Supplementary methods. 
 
Statistics 
Statistical analyses were performed using RStudio (V1.0.44) software. The threshold of TLS 
density was identified using the Receiver Operating Characteristics (ROC) curve analysis. 
Three years of PFS was set as the discriminant for short- and long-term survival. Neoadjuvant 
chemotherapy-treated patients (n=51) as well as chemotherapy-naïve patients whose follow-
up was shorter that 3 years without relapse (n=8) where excluded from this analysis. The 
prognostic significance of TLS density was assessed by the Kaplan-Meier curve, univariate 
and multivariate Cox regression analyses. Patients who died up to one month after surgery 
(n=6) were excluded from progression-free (PFS) and disease-free survival (DFS) analysis. 
PFS was calculated from date of surgery for patients with complete resection (R0) (n=121) or 
from the end date of adjuvant therapy for R>0 patients (n=11) until diagnosis of relapse. DFS 
was analyzed for R0 patients without pleural infiltration (n=118) from the date of surgery 
until the date of relapse. Disease-specific (DSS) and overall survival (OS) was defined as the 
number of days from surgery until death and was analyzed for all patients (n=138). Diagnosis 
of relapse or cancer-related death were considered as events for the PFS/DFS and DSS/OS 
analysis, respectively. Patients were censored at the day of last follow-up if lost from follow-
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up, diagnosed with a new unrelated tumor, died of a cancer non-related cause (not for OS), 
were alive (for DSS/OS) and not relapsed (for DFS/PFS). 
Quantification data are presented in dot plots with interquartile ranges and Turkey whiskers, 
or percent bar plots. Two-tailed Wilcoxon rank-sum test was used to compare all measured 
parameters between LSCC patient groups. For gene expression analysis, the Benjamini-and-
Hochberg method was used to correct the p values for multiple testing. The correlation 
between gene expression, histological and clinical parameters was assessed by the 
Spearman’s correlation or χ2 test with Yates’ correction. 
Multiple group comparison was done as follows: Quantification of TLS maturation in 
chemotherapy-naïve patients vs. neoadjuvant chemotherapy and radiotherapy-treated patients 
was compared by Kruskal-Wallis test with Dunn’s multiple comparison test. For the mouse 
experiment, groups were compared by the one-way ANOVA with Dunnett’s multiple 
comparison test. Alum only mice (group 2) were compared to negative control mice (group 1) 
and alum + Ova mice (group 3). Alum + Ova mice (group 3) were compared to alum only 
(group 2) and dexamethasone-treated mice (group 4). 
 
RESULTS 
 
The development of tumor-associated TLS follows sequential stages of maturation  
We initially assessed the presence of TLS in H&E-stained primary LSCC tissues using full 
diagnostic cases of 138 patients from the University Hospital Zurich (Table 1). We defined 
TLS as dense lymphocytic clusters and found that >95% of tumors contain such structures 
predominantly in the tumor periphery (Fig. 1A-C), especially in the broncho-alveolar tissues 
(Fig. 1D). In about 50% of tumors, we found TLS with a characteristic morphology of GC 
(Fig. 1A, arrowheads). Because such GC-containing TLS were highly similar to the 
secondary follicles in SLO (Fig. 1E, F) we proposed that TLS without GC represent the 
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analogues of the lymph node primary follicles, which contain mature FDC networks but lack 
GC. We used multi-parameter immunofluorescence (IF) to test this in serial LSCC sections 
spanning a depth of 250 µm. Indeed, TLS containing mature CD21
+
 FDC and lacking GC 
(CD23
-
) were present in the lungs of LSCC patients (Fig. 1G). Moreover, we observed a third 
TLS phenotype, namely dense lymphocytic clusters containing B and T cells without any 
apparent FDC networks or GC (Fig. 1H, I, Supplementary Fig. S2A). All three TLS 
phenotypes shared a common localization near CXCL13
+
 blood vessels (Fig. 1F-I, 
arrowheads, Supplementary Fig. S2A-C, arrowheads). Because CXCL13-expressing 
perivascular cells, B and T cells are essential for the development of TLS, we propose that 
clusters without FDC represent the first stage of TLS development and term these here as 
early TLS (E-TLS). In analogy to the stages of SLO follicles, we called FDC-containing TLS 
without GC as primary follicle-like TLS (PFL-TLS), and GC-containing TLS as secondary 
follicle-like TLS (SFL-TLS). 
Because HEVs and mature DCs are often located within TLS and their numbers are 
associated with improved outcome of cancer patients(12,39), we analyzed whether these cell 
types were associated with any particular TLS maturation stage by using multiparameter IF. 
We detected DC-LAMP+ (DCs) and PNAD+ cells (HEVs) in TLS at all maturation stages 
with similar frequencies (Fig. 1J) as well as in lymphocyte-rich areas without apparent 
organization into TLS (Fig. 1K, right). 
 
Tumor-associated TLS develop within a specialized microanatomical niche 
To identify factors involved in the development of LSCC-associated TLSs we selected a set 
of patients with high and low TLS densities and investigated the expression of chemokine 
transcripts associated with lymphoid neogenesis in lung inflammation (3,37). We found a 
significantly higher expression of CXCL13, LTB and CCL21 in TLS-high LSCCs (Fig. 2A). 
Due to high intergroup variability we did not detect a significant difference in the expression 
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of CXCL12 between TLS-high and TLS-low patients. Nevertheless, we found a direct 
correlation between CXCL12 expression and TLS density by Spearman correlation analysis 
(R=0.44, p=0.019), while IL-17A, CCL19 and other previously published TLS-associated 
factors did not correlate (Supplementary Table S5). 
We analyzed the expression of the relevant chemokines in LSCC tissues and found that 
CCL21 was expressed by HEVs within TLS, and CXCL13 by perivascular and TLS-
associated stromal cells as well as by 75% of tumors (Supplementary Fig. S3A). CXCL12, 
which is produced by alveolar and bronchial epithelium in steady state, was highly expressed 
by 90% of the tumors and by focal clusters of hyperplastic epithelial cells nearby TLS 
(Supplementary Fig. S3A). Cells in such clusters also expressed variable amounts of PD-L1 
and LTB (Fig. 2B-D, Supplementary Fig. S3B). We observed such clusters in all patients 
with TLS in the alveolar compartment and independently of the TLS maturation stage (Fig. 
2D). Taken together, lung parenchyma provides a favorable environment for TLS 
development, which involves CXCL13 production by perivascular and stromal cells, CCL21 
production by HEVs as well as LTB, PD-L1 and CXCL12 production by hyperplastic 
alveolar epithelial cells. 
 
The density of LSCC-associated TLS predicts survival and is associated with an 
adaptive immune response-related signature  
To test the prognostic significance of TLS density in our cohort we defined a threshold for 
separating patients with high and low TLS densities by ROC curve analysis (Fig. 3A). In 
Kaplan-Meier analysis high TLS density (>0.165 TLS/mm
2
) significantly correlated with 
improved progression-free (PFS), disease-free and overall survival (Fig. 3B). Among the 
significant covariates (Table 1) TLS density and tumor stage were the only two independent 
predictors of PFS in a multivariate Cox regression analysis (Supplementary Table S6). We 
confirmed the positive correlation between high TLS density and improved survival in 
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another, geographically distinct NSCLC patient cohort (Supplementary Table S1) by 
scoring TLS density in a single H&E image per patient (Supplementary Fig. S4A). 
To understand the possible reasons of the prognostic benefit, we investigated whether TLS are 
associated with the immunological makeup of a tumor. We compared the expression of 
various immune response-related genes (Supplementary Table S5) in a set of TLS-high and 
TLS-low patients. The expression of transcripts related to adaptive immunity including CD27, 
CD8A, IL-21, IGKC and others (Fig. 3C) was significantly upregulated in TLS-high tumors 
or directly correlated with TLS density (Supplementary Fig. S4B). Whereas the expression 
of innate response-related genes such as NKP46 and ITGAM (encoding CD11b) was similar in 
both patient groups (Supplementary Table S5). The expression of most TLS-associated 
genes was prognostic forth improved PFS in an independent LSCC cohort (n=141) available 
from the online repository, Kaplan-Meier plotter (40) (Supplementary Fig. S4C). Taken 
together, high TLS density is an independent positive prognostic marker for LSCC patients 
and suggests an increased intratumoral adaptive immune response.  
 
Neoadjuvant chemotherapy impairs TLS maturation and abrogates the prognostic 
power of TLS 
Histology analysis revealed a strong positive correlation between TLS density and the 
presence of GC (Fig. 4A), and a negative correlation between GC and the use of neoadjuvant 
chemotherapy (Supplementary Table S7). A significantly lower proportion of neoadjuvant 
chemotherapy-treated patients showed GC
+
 TLS (Fig. 4B) compared to chemotherapy-naïve 
patients, while TLS density was similar (Fig. 4C). We performed an in-depth analysis of TLS 
maturation in different patients groups using multiparameter IF and quantitative pathology 
(Fig. 4D). We determined the number of TLS in each maturation stage and compared the 
proportion of each stage in patients with high and low TLS densities and in patients after 
neoadjuvant chemotherapy. TLS maturation significantly correlated with TLS density in 
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chemotherapy-naïve patients (Spearman R= 0.32, p=0.01), but not in chemotherapy-treated 
patients (Spearman R= -0.09, p=0.6) Specifically, TLS maturation was arrested at the E-TLS 
stage in TLS-low patients (Fig. 4E, left panel) resulting in a significantly reduced SFL-TLS 
proportion (Fig. 4E, right panel) and decreased GC size (Fig. 4F) when compared to TLS-
high patients.  
To determine the impact of neoadjuvant therapy on TLS maturation we analyzed only TLS-
high patients and observed that the proportion of SFL-TLS (Fig. 4G) as well as GC size (Fig. 
4H) was significantly reduced in patients after neoadjuvant radio- or chemotherapy. Because 
neoadjuvant chemotherapy is used for patients with advanced disease, we separately 
compared TLS maturation in chemotherapy-naïve patients with early- and late-stage disease. 
We observed that only early-stage patients had a significantly higher proportion of SFL-TLS 
than chemotherapy-treated patients, while GC size was significantly higher in both early- and 
late-stage chemotherapy-naïve patients (Supplementary Fig. S5A, B). 
Because GC result from cognate interactions between T and B cells, their presence in TLS 
may point towards an ongoing immune response, which may be tumor-specific. We thus 
hypothesized that the reduction of GC in neoadjuvant chemotherapy-treated patients indicates 
dysfunctional TLS and abrogates the prognostic relevance of TLS density. Indeed, in 
neoadjuvant chemotherapy-treated patients TLS density had no prognostic power (Fig. 4I). In 
contrast, TLS density was an independent prognostic marker, stronger than tumor stage in 
chemotherapy-naïve patients (Table 2). To verify the prognostic relevance of TLS maturation 
in the absence of potential negative impact of chemotherapy we determined the association 
between the number of each TLS maturation stage determined in the IF images and the 
progression-free survival in chemotherapy-naïve patients. Only the number or the proportion 
of SFL-TLS significantly correlated with improved survival (Supplementary Fig. S5C-E). 
Taken together, these data show that neoadjuvant therapy impairs TLS maturation and reveal 
the essential role of GC for the prognostic power of TLS density in patients with LSCC. 
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Corticosteroids impair TLS development in the lungs 
The cytotoxic effects of chemo- and radiotherapy may have a negative impact on the rapidly 
proliferating GC B cells thus leading to GC shrinkage; however, all patients receiving 
neoadjuvant therapy were also concomitantly treated with corticosteroids to manage side 
effects. Thus we hypothesized that the immunosuppressive properties of corticosteroids 
negatively influence TLS development. To investigate this possibility we compared TLS 
density and maturation in neoadjuvant therapy-naïve LSCC patients, who were treated with 
corticosteroids before resection because of non-cancer-related comorbidities (Supplementary 
Table S4) or who had not received corticosteroids. Tumors of corticosteroid-treated patients 
showed a significantly lower TLS density, reduced proportion of SFL-TLS as well as GC size 
(Fig. 5A-C), independently of whether steroids were given locally or systemically.  
To provide direct experimental evidence for our observation that corticosteroids interfere with 
lung TLS development and/or maturation, we induced TLS in the lungs of mice by intranasal 
(i.n.) administration of alum with or without Ova as an antigen (adapted from (33)) and 
investigated the impact of systemic low-dose dexamethasone treatment (Fig. 5D). We 
characterized TLS maturation by multiparameter IF using B220, CD21/35 and PNA to stain B 
cells, FDC and GC, respectively. We observed that TLS development in response to i.n. alum 
followed the same maturation stages as in LSCC patients (Fig. 5E). However, the addition of 
Ova was necessary to induce high TLS density and GC formation (Fig. 5F-G). Systemic 
dexamethasone treatment did not significantly affect B cell, T cell and myeloid cell 
proportions in the spleen (Fig. 5H) and did not affect the density of TLS in the lungs (Fig. 
5G) but significantly reduced the proportion of PFL- and SFL-TLS (Fig. 5H). Collectively, 
our data suggest that corticosteroids have a negative impact on TLS development in the lungs 
independently of cytotoxic therapies. 
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DISCUSSION 
 
We performed a comprehensive analysis of LSCC tissues to study TLSs as whole 
microanatomical structures. Healthy human lungs are devoid of TLS (34), while most LSCC 
patients had peritumoral TLS in close vicinity to hyperplastic alveolar epithelial cells, which 
express CXCL12 and LTB. A fraction of these cells expressed considerable amounts of PD-
L1 rather than chemokines. Cells with similar morphology are present next to TLS in infected 
human lungs (41) and in advanced-stage COPD patients where they generate an alveolar-
lymphoid interface containing antigen-capturing DC (42). We propose that these cells support 
TLS development as we observed them close to TLS in all patients and at all TLS maturation 
stages. Our observation that the pleural wall, which lacks such cells, contained significantly 
less TLS than the alveolar compartment (Fig. 1D) supports this idea. However, direct 
experimental evidence is needed to verify this assumption. The morphology of this cell cluster 
resembles the dome-shaped lymphoepithelium (M cells) of the gut-associated TLS, which has 
a unique ability to transport antigens from the gut lumen to the underlying DC (43). M cell-
like cells are present also in the respiratory tract of various animal species and deliver material 
from the airway lumen to DCs in the underlying lymphoid follicles (44,45). Whether the 
hyperplastic epithelial cells surrounding TLS in human lungs likewise participate in antigen 
delivery to TLS is currently unknown.  
We showed that expression of CXCL13, LTB, CCL21 and CXCL12 correlates with TLS 
density in LSCC. In contrast, IL-17A and other chemokines relevant for iBALT formation in 
different lung inflammatory conditions (34) do not seem to be involved in the generation of 
LSCC-associated TLS. In the lungs, B cells are the main source of CXCL13 in response to 
cigarette smoke or LPS and are plausible drivers of TLS development in the lungs of COPD 
patients via Toll-like receptor and LTBR signaling (29). In LSCC, however, CXCL13 was 
mainly produced by TLS-associated perivascular and stromal cells and may serve as entry 
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sites for lymphocytes from the blood stream. We thus propose that B cell and T cell clusters 
without differentiated FDCs near CXCL13
+
 blood vessels represent the initial stage of TLS 
development. Various stimuli including IL-1 (46,47) and cigarette smoke (48) induce the 
production of CXCL13 in lung mesenchymal cells. However, the mechanisms driving the 
expression of CXCL13 by perivascular cells or the formation of the hyperplastic TLS-
associated epithelium in LSCC are currently unknown.  
In mice, naïve B cells respond to CXCL13 by producing LTB (49), which is crucial for the 
differentiation of FDCs from perivascular mesenchymal precursors and TLS development 
(36). We observed that hyperplastic epithelial cells and lymphocytes within early TLS 
produce LTB (Fig. 2C), which might drive the differentiation of FDC and generate the PFL-
TLS in human lungs. The subsequent establishment of SFL-TLSs presumably requires 
antigen-dependent interactions between DCs, T cells and B cells. CCL21 is mainly expressed 
by HEVs and lymphatic vessels, and attracts DCs and T cells to the developing TLS in 
different tissues (7). Our data suggest an upstream function of DCs and HEVs in the 
development of TLS because they are already present in E-TLS as well as in lymphocyte rich 
areas without apparent organization. However, it is currently unclear if such areas are the 
initiation sites of TLS or how these cell types dictate the generation of a mature TLS. We 
observed that TLS development follows the same steps in CRC (50) and in the lungs of mice 
after i.n. administration of alum + Ova. Thus, the described TLS maturation sequence may 
represent a general mechanism of TLS development. A clear understanding of TLS dynamics 
in the tumor microenvironment is currently lacking. It has been shown in the context of viral 
lung infection that TLS persist in lungs for at least 4 weeks after the clearance of the virus (4), 
however, it is unclear whether each single TLS was maintained for at least 4 weeks or 
whether TLS developed and disappeared at a certain rate during these 4 weeks. Tumor models 
with synchronized TLS development could be used to address this question; targeting of 
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LIGHT to tumor vasculature (24) may represent such a model, although it is currently 
unknown whether GC develop in this setting. 
We identified TLS density as the most significant and independent prognostic marker in 
untreated LSCC patients, which even outperformed tumor stage. Because TLS often correlate 
with increased lymphocytic infiltrate that has a pronounced prognostic benefit on its own (8), 
the causal relationship between TLS and lymphocytic infiltrate is unclear. Here we 
demonstrate that TLS and not the diffuse infiltration of lymphocytes or plasma cells is an 
independent prognostic factor for progression free survival (Table 2, Supplementary Table 
S6), suggesting that at least in LSCC, the structural organization of lymphocytes is the 
confounding factor for prognosis.  
TLS density can be assessed in diagnostic H&E sections and can thus be easily introduced in 
routine pathology to serve as a relevant prognostic parameter. Neoadjuvant chemotherapy-
treated patients, however, showed similar TLS density but significantly less and smaller GC 
when compared to untreated patients. Due to the lack of paired pre- and post-therapy samples 
we cannot exclude that neoadjuvant chemotherapy-treated patients had a reduced TLS 
maturation already before the therapy. Nevertheless, we did observe a significant reduction in 
GC size when compared to stage-matched chemotherapy-naïve patients (Supplementary Fig. 
S5B). In mice, de novo formation of B cell follicles and the growth of GC size is crucial for 
an effective immune response (51). We thus propose that the low frequency and reduced size 
of GC in tumor-associated TLS after neoadjuvant chemotherapy reflects impaired TLS 
function. This is in line with the observation that the prognostic power of TLS density was 
lost in these patients. Further, we demonstrate that only SFL-TLS but not E-TLS or PFL-TLS 
correlated with improved survival in chemotherapy-naïve patients. The notion that the 
presence of GC reflects the function of TLS in anti-tumor immunity is also supported by 
Posch et al. showing that the integration of TLS maturation and TLS density into a joint TLS 
immunoscore had a superior predictive power for the recurrence risk in untreated non-
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metastatic CRC than TLS density alone (50). However, direct evidence for the presence and 
activation of tumor-specific B and/or T cells in cancer-associated TLS is still lacking. 
We propose that corticosteroids are at least partly responsible for the impaired TLS 
development in the neoadjuvant chemotherapy-treated LSCC patients for the following 
reasons. First, we observed a significantly lower TLS density and reduced GC formation in 
LSCC patients who were treated with corticosteroids but did not receive neoadjuvant 
chemotherapy. Second, we observed that dexamethasone significantly decreased the 
development of alum + Ova-induced mature TLS in the lungs of mice. Third, corticosteroid-
treated COPD patients have a significantly reduced TLS density in comparison to COPD 
patients who did not receive corticosteroids (52). Finally, corticosteroid treatment abolishes 
the formation of GC in BALT in experimental rat pulmonary granuloma (53). A possible 
explanation is offered by a study demonstrating that prednisolone induces apoptosis of human 
GC B cells by blocking both surface immunoglobulin- and CD40-mediated survival pathways 
(54). Despite the concomitant use of corticosteroids, the TLS density in chemotherapy-treated 
patients was not diminished. We propose that chemotherapy-induced inflammation in the 
tumor microenvironment (55) overrides the negative impact of steroids on TLS initiation 
(reflected by total TLS density), but is not sufficient to override the negative impact on GC 
maturation (reflected by proportion of SFL-TLS). Similarly, in the lungs of mice receiving 
proinflammatory alum i.n., steroid treatment did not decrease TLS density (Fig. 5F) whereas 
it reduced TLS maturation (Fig. 5G). Our findings indicate that corticosteroid treatment of 
cancer patients may not only decrease their spontaneous immune defense to cancer but also 
suppress the response to immunotherapy as well as to treatments that induce immunogenic 
cell death such as radiotherapy (56) and chemotherapy (57). Thus the use of alternative non-
steroid drugs for managing adverse effects of chemo-, radio- or immune therapy should be 
considered.  
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In summary, the work presented here extends the current knowledge by (1) characterizing the 
niche that fosters TLS development in the lungs, (2) determining stages of TLS maturation 
that affect the prognostic relevance of TLS density, and (3) discovering the negative impact of 
corticosteroids on TLS development in LSCC that is associated with poor outcome in 
chemotherapy-naïve patients. 
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TABLES 
 
Table 1. Clinical and histological characteristics of the LSCC patient cohort (n=138) 
from the University Hospital Zurich 
Characteristics Number % 
Median 
PFS 
HR
a 
 (CI 95%) 
Characteristics Number % 
Median 
PFS 
HR
a 
(CI 95%) 
Gender Male 111 80.4 827 1.1 Grade 2 61 44.2 1060 1.1 
 Female 27 19.6 1060 (0.6-2.1)  3 77 55.8 725 (0.55-1.83) 
Age (Mean±SEM 63±0.8)  1 Tumor Size (Mean±SEM 4.3±0.2) 1.2*** 
< Median 60 43.5 894 (0.97-1) < Median 67 48.6 1471 (1.1-1.3) 
= Median (62) 12 8.7 1236  = Median (3.8) 4 2.9 415  
> Median 66 47.8 796  > Median 67 48.6 451  
Smoking history    0.9 Pleural Invasion   1.5 
Current 79 57.2 1172 (0.7-1.8)  Yes 41 29.7 509 (0.92-2.5) 
Former 59 42.8 555   No 97 70.3 1123  
Pack-years (Mean±SEM 52±2)  1 Vascular Invasion   1.6 
< Median  56 40.6 533 (0.99-1)  Yes 55 39.9 414 (0.97-2.6) 
= Median (50)  22 15.9 1539   No 83 60.1 1146  
> Median 56 40.6 916  Adjuvant therapyc 1.9** 
ND 4 2.9 1187  Chemotherapy 23 16.7 509 (1.3-2.8) 
pT/ypT 0 7 5.1 1434 1.3*** Radiotherapy 16 11.6 339  
 1a 26 18.8 1390 (1.1-1.5) Chemo+Radio 5 3.6 414  
 1b 13 9.4 2167  None 94 68.1 1162  
 2a 27 19.6 1123  Corticosteroid treatmentd 1.2 
 2b 11 8.0 1055  Local 12 8.7 627 (0.74-2) 
 3 31 22.5 652  Systemic 57 41.3 495  
 4 23 16.7 360  None 63 45.7 1172  
pN 0 62 44.9 1394 1.7** ND 6 4.3 720  
 1 48 34.8 761 (1.2-2.3) TLS densitye    0.4** 
 2 28 20.3 418  TLS-low 47 34.1 451 (0.26-0.71) 
pM 0 132 95.7 1058 7.3*** TLS-high 91 65.9 1381  
 1a 3 2.2 180 (2.9-18) GC formationf  0.6 
 1b 3 2.2 2  No 53 38.4 495 (0.39-1) 
Stage 0 6 4.3 1518 1.4*** Yes 85 61.6 1123  
 1a 22 15.9 1678 (1.2-1.7) TIL score (Mean±SEM 4.1±0.1) 0.75* 
 1b 10 7.2 1073  < Median 47 34.1 461 (0.6-0.93) 
 2a 29 21.0 1283  = Median (4) 21 15.2 410  
 2b 16 11.6 797  > Median 57 41.3 1178  
 3a 43 31.2 414  ND 13 9.4 1511  
 3b 8 5.8 512  Plasma cell score (Mean±SEM 3.2±0.2) 0.81* 
 4 4 2.9 91  < Median 56 40.6 465 (0.7-0.94) 
Neoadjuvant chemotherapy
b 1 = Median (3.5) 9 6.5 1055  
 Yes 51 37.0 495 (0.62-1.7) > Median 60 43.5 1426  
 No 87 63.0 1060  ND 13 9.4 1511  
PFS, progression-free survival; HR, hazard ratio; TLS, tertiary lymphoid structures; GC, 
germinal centers; ND, not determined. 
TNM was assessed according to the 7
th
 Edition of the TNM Staging System for non-small cell 
lung cancer. 
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a 
HR was calculated by the univariate Cox regression analysis for PFS comparing no vs. yes 
or low vs. high groups in case of categorical variables (pleural invasion, vascular invasion, 
neoadjuvant and adjuvant chemotherapy, steroid treatment, GC formation, TLS density) or 
comparing low to increasing values for continuous variables (age, pack years, pT, pN, pM, 
stage, grade, size). P-values according to Wald-test: *<0.05, **<0.005, ***<0.0005. Patients 
that had died sooner than 1 month after surgery were excluded from this analysis (n=6). 
b
 For neoadjuvant chemotherapy platinols were used in combination with either gemcitabine 
(n=19) or taxols (n=27) or others (n=5). 
c
 HR was calculated for all neoadjuvant chemotherapy-treated patients vs. untreated patients. 
d
 Treatment of corticosteroids was considered if applied up to one month before surgery. All 
neoadjuvant chemotherapy-treated patients received systemic corticosteroids. Eighteen 
chemotherapy-naïve patients received corticosteroids because of cancer non-related 
comorbidities either systemically or locally (inhalation). HR was calculated for all steroid-
treated vs. untreated patients. 
e 
TLS density was measured as the number of TLS per mm
2
 in the tumor periphery and 
defined as high if >0.165 TLS/mm
2
. 
f
 A tumor was considered GC-positive if at least one TLS showed the characteristic 
morphology of proliferating centroblasts. 
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Table 2. Multivariate Cox regression analysis of progression-free survival of 
neoadjuvant chemotherapy-naïve patients (n=85) 
 
Variables in the 
equation 
p-value 
Hazard 
Ratio 
95% CI 
Lower Upper 
Model 1
a
 
Stage
b
 0.007 1.38 1.1 1.73 
Adjuvant therapy
c
 0.95 1 0.61 1.69 
TLS density
c
 0.0003 0.28 0.14 0.56 
TIL score
b
 0.5 0.88 0.61 1.28 
Plasma cell score
b
 0.84 0.97 0.75 1.27 
Model 2
a
     
Stage
c
 0.006 2.7 1.33 5.43 
Adjuvant therapy
c
 0.94 1 0.61 1.72 
TLS density
c
 0.0002 0.26 0.13 0.52 
TIL score
b
 0.35 0.84 0.59 1.21 
Plasma cell score
b
 0.96 1 0.77 1.32 
Model 3
a
     
pT/ypT
b
 0.011 1.32 1.1 1.63 
pN
b
 0.59 1.13 0.72 1.8 
pM
b
 0.11 4.2 0.73 24 
Adjuvant therapy
c
 0.66 1.13 0.65 1.95 
TLS density
c
 0.002 0.34 0.17 0.67 
TIL score
b
 0.29 0.82 0.56 1.19 
Plasma cell score
b
 0.87 0.98 0.74 1.29 
A
 Stage was analyzed either as a continuous variable (lower to higher) or as a categorical 
variable (early stage (0-2a) vs. late stage (3a-4)) in separate models. Because stage is 
dependent on TNM parameters we analysed these in a separate model. 
B
 Continuous variables (smaller to larger) 
C
 Categorical variables (no vs. yes or low vs high) 
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FIGURE LEGENDS 
 
Figure 1. Development of LSCC-associated TLS. (A) A representative image of H&E-
stained LSCC showing TLS in the adjacent normal tissue (N) in close proximity to the 
invasive front (white dashed line) of the tumor (T). GC in TLS were identified by a lighter 
central area (arrowheads, and left zoomed-in segment). Scale bar 500 μm. (B, C) The number 
of dense lymphocytic aggregates was determined in peritumoral lung parenchyma (B), and 
intratumoral regions (C) in 138 LSCC patients. The number of TLS per mm
2
 defined the TLS 
density for each patient. (D) TLS density was compared in broncho-alveolar tissue (n=138) 
and pleura where possible (n=14) by 2-tailed Wilcoxon rank-sum test. (E) The structure and 
phenotype of GC-containing TLS was analysed in serial FFPE LSCC tissues from 5 patients 
with high TLS density by IHC. Scale bar 100 μm (F-H) IF staining for FDCs (CD21), GC 
cells (CD23) and CXCL13 was performed on serial sections spanning a depth of 250 μm of 2 
LSCC patients with high TLS density. Slides were imaged using the multispectral microscopy 
system Vectra 3.0 (PerkinElmer). Each TLS was evaluated through the different depths and 
the images showing the widest TLS diameter (the central part) are shown. SFL-TLS, 
secondary follicle-like TLS with a GC reaction (white circle); PFL-TLS, primary follicle-like 
TLS with differentiated FDCs (white circle); E-TLS, early TLS. Arrowheads indicate the 
TLS-associated CXCL13
+
 blood vessel. See also Supplementary Fig. S2. (I) IF staining for 
T cells (CD3), B cells (CD20) and CXCL13 was performed for 5 LSCC patients with high 
TLS density. Slides were imaged by AxioScan (Zeiss). A representative image showing dense 
lymphocytic cluster forming around a CXCL13
+
 blood vessel (arrowhead) is shown. Scale 
bars 100 μm. (J-K) IF staining for FDCs (CD21), GC cells (CD23), B cells (CD20), DCs 
(DC-LAMP) and HEVs (PNAD) was performed on sections from 5 LSCC patients with high 
TLS density. (J) The number of TLS positive for HEVs and DCs was determined and 
compared in each TLS maturation stage. (K) Representative images of TLS in each 
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maturation stage and non-organized lymphocytic infiltrate containing DCs (white arrowheads) 
HEVs (magenta arrowheads) and DC-LAMP expressing lung epithelial cells (cyan 
arrowheads) are shown. 
 
Figure 2. A specialized niche supports TLS development. (A) qRT-PCR analysis for 
transcripts of genes involved in lymphoid neogenesis was performed for chemotherapy-naïve 
patients with TLS-low (n=10) and TLS-high tumors (n=17). Relative expression (2
Ct(cohort 
mean)-Ct(target gene)
)
 
was normalized against the normalization factor (NF) calculated using three 
most stable reference genes in the selected cohort. Groups were statistically compared using 
the 2-tailed Wilcoxon rank-sum test with Benjamini and Hochberg correction for multiple 
testing. (B-D) Multiparameter-IF was performed in 5 LSCC patients with high TLS density 
for CXCL12, LTB, PD-L1 and cell type markers CDH1 (E-cadherin), CD45, CD21, and 
CD23. Representative images of hyperplastic TLS-associated epithelium are shown. Slides 
were imaged using a laser scanning confocal microscope (Leica) (B, C) or the Vectra imaging 
system (D). Scale bar 50 μm. See also Supplementary Fig. S3. 
 
Figure 3. TLS density correlates with improved survival and adaptive immune response. 
(A, B) TLSs were quantified in H&E sections as described in Fig. 1. (A) ROC curve analysis 
was performed on chemotherapy-naïve patients with complete 3 year follow-up data (n=79) 
and identified 0.165 TLS/mm
2
 as a threshold for separating TLS-high and TLS-low tumors 
with prognostic relevance. AUC, area under the curve. (B) Survival was compared for 
patients with high (>0.165 TLS/mm
2
) and low TLS density by Kaplan-Meier curves. 
Confidence intervals are indicated as shaded areas surrounding survival curves. Significance 
was calculated by log-rank test. Patient numbers per group are indicated in brackets and 
numbers at risk are displayed for each 1000 days of follow-up. (C) qRT-PCR analysis for 
immune response-related transcripts was performed as described in Fig. 2. Groups were 
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compared using the 2-tailed Wilcoxon rank-sum test with Benjamini and Hochberg correction 
for multiple testing. See also Supplementary Fig. S4. 
 
Figure 4. The prognostic value of TLS density is abrogated after neoadjuvant 
chemotherapy due to impaired GC formation. (A) TLS density was analyzed in H&E 
sections as described in Fig. 1B. A tumor was considered GC-positive if at least one TLS 
showed the characteristic morphology of proliferating centroblasts. TLS density was 
compared in patients with apparent GC (n=85, GC+) vs. no GC (n=53, GC-) by 2-tailed 
Wilcoxon rank-sum test. (B) The proportion of patients with GC
+
 TLS in TLS-high patients 
with (n=37) or without (n=55) neoadjuvant chemotherapy (-/+ NeoCh), and TLS-low patients 
with (n=14) and without (n=34) neoadjuvant chemotherapy. χ2 test with Yates’ correction 
was used to compare the proportion of patients with GC
+
 TLS in +NeoCh and -NeoCh groups 
(p=0.012). (C) TLS density was compared in chemotherapy-naïve patients (-NeoCh, n=87) 
and -treated patients (+NeoCh, n=51) by 2-tailed Wilcoxon rank-sum test. (D) Quantitative 
pathology approach: IF was performed for B cells (CD20), T cells (CD3) and epithelial cells 
(panCK) (top row) or FDCs (CD21), GCs (CD23) and CXCL13 (middle row). To analyze 
TLS maturation stages and GC size tissue segmentation algorithm was trained to recognize 
dense DAPI cell clusters as lymphocytic aggregates, CD21
+
 areas as FDC and CD21
+
CD23
+
 
areas as GC (bottom row). The number of TLS in each maturation stage was determined and 
expressed as the proportion of all TLS for each patient. GC size was measured as the average 
number of pixels per GC area in each patient. (E, F) TLS maturation and GC size compared 
in chemotherapy-naïve patients with high (n=37) or low TLS density (n=24) by 2-tailed 
Wilcoxon rank-sum test. (G, H) TLS maturation and GC size were compared in TLS-high 
chemotherapy-naïve (-, n=37), neoadjuvant chemotherapy-treated (+Ch, n=28) or 
radiotherapy-treated (+RT, n=4) patients by 2-tailed Wilcoxon rank-sum test. The same 
significant differences were detected by the Kruskal-Wallis test with Dunn’s multiple 
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comparison test comparing naïve vs. +Ch and naïve vs +RT groups. (I) Patients were 
stratified by neoadjuvant chemotherapy treatment and progression-free survival was 
compared in patients with high and low TLS density as described in Fig. 3. Patient numbers 
per group are indicated in brackets and numbers at risk are displayed for each 1000 days of 
follow-up. 
 
Figure 5. TLS maturation is hampered by corticosteroids. (A) TLS density was analyzed 
in H&E-stained sections as described in Fig. 1. TLS density was compared in chemotherapy-
naïve patients with no history of steroid treatment (n=63) and patients who received steroids 
until at least one month before surgery (n=18) by 2-tailed Wilcoxon rank-sum test. (B, C) 
TLS maturation and GC size were compared in a selection of chemotherapy-naïve patients as 
described in Fig. 4. Steroid-treated patients (n=15) were compared to untreated patients 
(n=43) by 2-tailed Wilcoxon rank-sum test. (D) Experimental design for TLS induction by i.n. 
administration of alum (200 μg/mouse)  and ovalbumin (Ova, 50 μg/mouse) (adapted from 
(33)) and dexamethasone treatment (0.3 mg/kg). (E) Representative images of mouse lungs 
stained by IF to visualize different TLS maturation stages. Slides were imaged by Vectra 3.0. 
Scale bars 100 μm. (F) TLS density was determined as the number of dense B cell aggregates 
per lung lobe and compared in mice after TLS induction and dexamethasone treatment by 
one-way ANOVA and Dunnett’s multiple comparison test. (G) TLS maturation stages were 
analyzed as described in Fig. 4 with CD21/35
+
 areas recognized as FDCs and CD21/35
+
PNA
+
 
areas recognized as GCs; PNA also stains alveolar epithelium. (H) Spleens were collected at 
the time of sacrifice (Fig. 5D) and analyzed by flow cytometry. The following gates were 
applied prior to gating on the target populations: singlets/live cells/CD45
+
. The proportions of 
B cells (B220
+
), T cells (TCRβ+) and myeloid cells (CD11b+) from live cells is indicated. (F-
H) Different treatment groups were compared by one-way ANOVA and Dunnett’s multiple 
comparison test. 
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